Pregabalin misuse in methadone maintenance treatment patients in Israel: Prevalence and risk factors
•Methadone maintenance treatment patients misuse pregabalin.•High prevalence (17.7%) of pregabalin was detected in urine tests.•Risk factors includes benzodiazepine and high depressive score.•Pregabalin misuse was detected also in patients with take-home medication privileges. Drug users reportedly...
Gespeichert in:
| Veröffentlicht in: | Drug and alcohol dependence 2018-08, Vol.189, p.8-11 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 11 |
|---|---|
| container_issue | |
| container_start_page | 8 |
| container_title | Drug and alcohol dependence |
| container_volume | 189 |
| creator | Sason, Anat Adelson, Miriam Schreiber, Shaul Peles, Einat |
| description | •Methadone maintenance treatment patients misuse pregabalin.•High prevalence (17.7%) of pregabalin was detected in urine tests.•Risk factors includes benzodiazepine and high depressive score.•Pregabalin misuse was detected also in patients with take-home medication privileges.
Drug users reportedly abuse pregabalin, and its combination with opiates was related to fatalities. We aimed to estimate the prevalence of pregabalin misuse and risk factors among patients in methadone maintenance treatment (MMT).
A cross-sectional study included all current MMT patients (n = 300) after excluding 9 with prescriptions, from a large tertiary medical center university-affiliated MMT clinic in Israel. Pregabalin was tested in one of the routine urine tests for other substances in December 2017. Data on urine results and patients’ characteristics were retrieved from the patients’ records.
Pregabalin was detected among 53 (17.7%) patients. The group had higher depressive symptoms severity score (21-HAM-D) (11.1 ± 8.4 vs. 8.3 ± 7.8, p = 0.03), a higher prevalence of sero-positive HIV (13.7% vs. 4.2%, p = 0.02), sero-positive hepatitis C (66.7% vs. 50.4%, p = 0.04), DSM-IV-TR Axis I psychiatric diagnosis (54.0% vs. 41.7%, p = 0.03), and positive urine for opiates (22.6% vs. 8.9%, p = 0.008), cannabis (39.6% vs. 4.0 p |
| doi_str_mv | 10.1016/j.drugalcdep.2018.04.025 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2049556053</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0376871618302916</els_id><sourcerecordid>2100878650</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-c5411f2e1ceb9130c1fc48fd41ebdd474364a785b9a883b2debc24666c3391d13</originalsourceid><addsrcrecordid>eNqFkctu1TAQhi0EoofCKyBLbNgkjC9xHHZQcalUCRawthx7UnxInIPtVOLtcXQKSGyYzczim9v_E0IZtAyYenVsfdpu7ew8nloOTLcgW-DdA3Jguh8aAKkekgOIXjW6Z-qCPMn5CDXUAI_JBR901ws-HIj_nPDWjnYOkS4hbxnpXmH5Zv0akS42xILRRoe0JLRlwVjoyZZQc97Z65wszq9pHXRnZ9xBGz1NIX-nk3VlTfkpeTTZOeOz-3xJvr5_9-XqY3Pz6cP11ZubxkngpXGdZGziyByOAxPg2OSknrxkOHoveymUtL3uxsFqLUbucXRcKqWcEAPzTFySl-e5p7T-2DAXU19yOM824rplw0EOXaegExV98Q96XLcU63WGMwDda9VBpfSZcmnNOeFkTiksNv00DMzuhDmav06Y3QkD0lQnauvz-wXbuKD_0_hb-gq8PQNYFbkLmEx2YZfPh4SuGL-G_2_5BfwRn8Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2100878650</pqid></control><display><type>article</type><title>Pregabalin misuse in methadone maintenance treatment patients in Israel: Prevalence and risk factors</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Access via ScienceDirect (Elsevier)</source><creator>Sason, Anat ; Adelson, Miriam ; Schreiber, Shaul ; Peles, Einat</creator><creatorcontrib>Sason, Anat ; Adelson, Miriam ; Schreiber, Shaul ; Peles, Einat</creatorcontrib><description>•Methadone maintenance treatment patients misuse pregabalin.•High prevalence (17.7%) of pregabalin was detected in urine tests.•Risk factors includes benzodiazepine and high depressive score.•Pregabalin misuse was detected also in patients with take-home medication privileges.
Drug users reportedly abuse pregabalin, and its combination with opiates was related to fatalities. We aimed to estimate the prevalence of pregabalin misuse and risk factors among patients in methadone maintenance treatment (MMT).
A cross-sectional study included all current MMT patients (n = 300) after excluding 9 with prescriptions, from a large tertiary medical center university-affiliated MMT clinic in Israel. Pregabalin was tested in one of the routine urine tests for other substances in December 2017. Data on urine results and patients’ characteristics were retrieved from the patients’ records.
Pregabalin was detected among 53 (17.7%) patients. The group had higher depressive symptoms severity score (21-HAM-D) (11.1 ± 8.4 vs. 8.3 ± 7.8, p = 0.03), a higher prevalence of sero-positive HIV (13.7% vs. 4.2%, p = 0.02), sero-positive hepatitis C (66.7% vs. 50.4%, p = 0.04), DSM-IV-TR Axis I psychiatric diagnosis (54.0% vs. 41.7%, p = 0.03), and positive urine for opiates (22.6% vs. 8.9%, p = 0.008), cannabis (39.6% vs. 4.0 p < 0.0005) benzodiazepine (BDZ) (77.4% vs. 18.2%, p < 0.0005) and oxycodone (11.3% vs. 0.4%, p < 0.0005). Logistic regression found pregabalin group as more likely to be urine positive to BDZ (OR = 12.8 95%CI 5.0–32.5) cannabis (OR = 22.7, 95%CI 6.3–81.6) and oxycodone (OR = 43.9, 95%CI 3.6–541.4), with higher 21-HAM-D scores (OR = 1.1, 95%CI 1.04–1.2) and hepatitis C sera-positive (OR = 4.1, 95% CI 1.5–11.4). Unexpectedly, 13.2% of the pregabalin group had take-home dose privileges, which are rewards to non-drug abusers.
High prevalence of pregabalin misuse among both BDZ abusers and non-abusers and patients with depressive symptoms supports both the inclusion of routine monitoring for pregabalin and intervention in MMT population.</description><identifier>ISSN: 0376-8716</identifier><identifier>EISSN: 1879-0046</identifier><identifier>DOI: 10.1016/j.drugalcdep.2018.04.025</identifier><identifier>PMID: 29857329</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Abusers ; Benzodiazepines ; Benzodiazepines (BDZ) ; Cannabis ; Depression ; Drug abuse ; Drug addiction ; Drug use ; Health care facilities ; Hepatitis ; Hepatitis C ; HIV ; Human immunodeficiency virus ; Marijuana ; Medical diagnosis ; Medical treatment ; Mental depression ; Methadone ; Methadone maintenance treatment (MMT) ; Narcotics ; Opiates ; Opioids ; Oxycodone ; Patients ; Pregabalin ; Prescription drugs ; Rewards ; Risk analysis ; Risk factors ; Severity ; Substance abuse ; Symptoms ; Urine ; Urine tests</subject><ispartof>Drug and alcohol dependence, 2018-08, Vol.189, p.8-11</ispartof><rights>2018 Elsevier B.V.</rights><rights>Copyright © 2018. Published by Elsevier B.V.</rights><rights>Copyright Elsevier Science Ltd. Aug 1, 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-c5411f2e1ceb9130c1fc48fd41ebdd474364a785b9a883b2debc24666c3391d13</citedby><cites>FETCH-LOGICAL-c402t-c5411f2e1ceb9130c1fc48fd41ebdd474364a785b9a883b2debc24666c3391d13</cites><orcidid>0000-0002-7091-7987</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.drugalcdep.2018.04.025$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,30999,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29857329$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sason, Anat</creatorcontrib><creatorcontrib>Adelson, Miriam</creatorcontrib><creatorcontrib>Schreiber, Shaul</creatorcontrib><creatorcontrib>Peles, Einat</creatorcontrib><title>Pregabalin misuse in methadone maintenance treatment patients in Israel: Prevalence and risk factors</title><title>Drug and alcohol dependence</title><addtitle>Drug Alcohol Depend</addtitle><description>•Methadone maintenance treatment patients misuse pregabalin.•High prevalence (17.7%) of pregabalin was detected in urine tests.•Risk factors includes benzodiazepine and high depressive score.•Pregabalin misuse was detected also in patients with take-home medication privileges.
Drug users reportedly abuse pregabalin, and its combination with opiates was related to fatalities. We aimed to estimate the prevalence of pregabalin misuse and risk factors among patients in methadone maintenance treatment (MMT).
A cross-sectional study included all current MMT patients (n = 300) after excluding 9 with prescriptions, from a large tertiary medical center university-affiliated MMT clinic in Israel. Pregabalin was tested in one of the routine urine tests for other substances in December 2017. Data on urine results and patients’ characteristics were retrieved from the patients’ records.
Pregabalin was detected among 53 (17.7%) patients. The group had higher depressive symptoms severity score (21-HAM-D) (11.1 ± 8.4 vs. 8.3 ± 7.8, p = 0.03), a higher prevalence of sero-positive HIV (13.7% vs. 4.2%, p = 0.02), sero-positive hepatitis C (66.7% vs. 50.4%, p = 0.04), DSM-IV-TR Axis I psychiatric diagnosis (54.0% vs. 41.7%, p = 0.03), and positive urine for opiates (22.6% vs. 8.9%, p = 0.008), cannabis (39.6% vs. 4.0 p < 0.0005) benzodiazepine (BDZ) (77.4% vs. 18.2%, p < 0.0005) and oxycodone (11.3% vs. 0.4%, p < 0.0005). Logistic regression found pregabalin group as more likely to be urine positive to BDZ (OR = 12.8 95%CI 5.0–32.5) cannabis (OR = 22.7, 95%CI 6.3–81.6) and oxycodone (OR = 43.9, 95%CI 3.6–541.4), with higher 21-HAM-D scores (OR = 1.1, 95%CI 1.04–1.2) and hepatitis C sera-positive (OR = 4.1, 95% CI 1.5–11.4). Unexpectedly, 13.2% of the pregabalin group had take-home dose privileges, which are rewards to non-drug abusers.
High prevalence of pregabalin misuse among both BDZ abusers and non-abusers and patients with depressive symptoms supports both the inclusion of routine monitoring for pregabalin and intervention in MMT population.</description><subject>Abusers</subject><subject>Benzodiazepines</subject><subject>Benzodiazepines (BDZ)</subject><subject>Cannabis</subject><subject>Depression</subject><subject>Drug abuse</subject><subject>Drug addiction</subject><subject>Drug use</subject><subject>Health care facilities</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Marijuana</subject><subject>Medical diagnosis</subject><subject>Medical treatment</subject><subject>Mental depression</subject><subject>Methadone</subject><subject>Methadone maintenance treatment (MMT)</subject><subject>Narcotics</subject><subject>Opiates</subject><subject>Opioids</subject><subject>Oxycodone</subject><subject>Patients</subject><subject>Pregabalin</subject><subject>Prescription drugs</subject><subject>Rewards</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Severity</subject><subject>Substance abuse</subject><subject>Symptoms</subject><subject>Urine</subject><subject>Urine tests</subject><issn>0376-8716</issn><issn>1879-0046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNqFkctu1TAQhi0EoofCKyBLbNgkjC9xHHZQcalUCRawthx7UnxInIPtVOLtcXQKSGyYzczim9v_E0IZtAyYenVsfdpu7ew8nloOTLcgW-DdA3Jguh8aAKkekgOIXjW6Z-qCPMn5CDXUAI_JBR901ws-HIj_nPDWjnYOkS4hbxnpXmH5Zv0akS42xILRRoe0JLRlwVjoyZZQc97Z65wszq9pHXRnZ9xBGz1NIX-nk3VlTfkpeTTZOeOz-3xJvr5_9-XqY3Pz6cP11ZubxkngpXGdZGziyByOAxPg2OSknrxkOHoveymUtL3uxsFqLUbucXRcKqWcEAPzTFySl-e5p7T-2DAXU19yOM824rplw0EOXaegExV98Q96XLcU63WGMwDda9VBpfSZcmnNOeFkTiksNv00DMzuhDmav06Y3QkD0lQnauvz-wXbuKD_0_hb-gq8PQNYFbkLmEx2YZfPh4SuGL-G_2_5BfwRn8Q</recordid><startdate>20180801</startdate><enddate>20180801</enddate><creator>Sason, Anat</creator><creator>Adelson, Miriam</creator><creator>Schreiber, Shaul</creator><creator>Peles, Einat</creator><general>Elsevier B.V</general><general>Elsevier Science Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7091-7987</orcidid></search><sort><creationdate>20180801</creationdate><title>Pregabalin misuse in methadone maintenance treatment patients in Israel: Prevalence and risk factors</title><author>Sason, Anat ; Adelson, Miriam ; Schreiber, Shaul ; Peles, Einat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-c5411f2e1ceb9130c1fc48fd41ebdd474364a785b9a883b2debc24666c3391d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Abusers</topic><topic>Benzodiazepines</topic><topic>Benzodiazepines (BDZ)</topic><topic>Cannabis</topic><topic>Depression</topic><topic>Drug abuse</topic><topic>Drug addiction</topic><topic>Drug use</topic><topic>Health care facilities</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Marijuana</topic><topic>Medical diagnosis</topic><topic>Medical treatment</topic><topic>Mental depression</topic><topic>Methadone</topic><topic>Methadone maintenance treatment (MMT)</topic><topic>Narcotics</topic><topic>Opiates</topic><topic>Opioids</topic><topic>Oxycodone</topic><topic>Patients</topic><topic>Pregabalin</topic><topic>Prescription drugs</topic><topic>Rewards</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Severity</topic><topic>Substance abuse</topic><topic>Symptoms</topic><topic>Urine</topic><topic>Urine tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sason, Anat</creatorcontrib><creatorcontrib>Adelson, Miriam</creatorcontrib><creatorcontrib>Schreiber, Shaul</creatorcontrib><creatorcontrib>Peles, Einat</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Drug and alcohol dependence</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sason, Anat</au><au>Adelson, Miriam</au><au>Schreiber, Shaul</au><au>Peles, Einat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pregabalin misuse in methadone maintenance treatment patients in Israel: Prevalence and risk factors</atitle><jtitle>Drug and alcohol dependence</jtitle><addtitle>Drug Alcohol Depend</addtitle><date>2018-08-01</date><risdate>2018</risdate><volume>189</volume><spage>8</spage><epage>11</epage><pages>8-11</pages><issn>0376-8716</issn><eissn>1879-0046</eissn><abstract>•Methadone maintenance treatment patients misuse pregabalin.•High prevalence (17.7%) of pregabalin was detected in urine tests.•Risk factors includes benzodiazepine and high depressive score.•Pregabalin misuse was detected also in patients with take-home medication privileges.
Drug users reportedly abuse pregabalin, and its combination with opiates was related to fatalities. We aimed to estimate the prevalence of pregabalin misuse and risk factors among patients in methadone maintenance treatment (MMT).
A cross-sectional study included all current MMT patients (n = 300) after excluding 9 with prescriptions, from a large tertiary medical center university-affiliated MMT clinic in Israel. Pregabalin was tested in one of the routine urine tests for other substances in December 2017. Data on urine results and patients’ characteristics were retrieved from the patients’ records.
Pregabalin was detected among 53 (17.7%) patients. The group had higher depressive symptoms severity score (21-HAM-D) (11.1 ± 8.4 vs. 8.3 ± 7.8, p = 0.03), a higher prevalence of sero-positive HIV (13.7% vs. 4.2%, p = 0.02), sero-positive hepatitis C (66.7% vs. 50.4%, p = 0.04), DSM-IV-TR Axis I psychiatric diagnosis (54.0% vs. 41.7%, p = 0.03), and positive urine for opiates (22.6% vs. 8.9%, p = 0.008), cannabis (39.6% vs. 4.0 p < 0.0005) benzodiazepine (BDZ) (77.4% vs. 18.2%, p < 0.0005) and oxycodone (11.3% vs. 0.4%, p < 0.0005). Logistic regression found pregabalin group as more likely to be urine positive to BDZ (OR = 12.8 95%CI 5.0–32.5) cannabis (OR = 22.7, 95%CI 6.3–81.6) and oxycodone (OR = 43.9, 95%CI 3.6–541.4), with higher 21-HAM-D scores (OR = 1.1, 95%CI 1.04–1.2) and hepatitis C sera-positive (OR = 4.1, 95% CI 1.5–11.4). Unexpectedly, 13.2% of the pregabalin group had take-home dose privileges, which are rewards to non-drug abusers.
High prevalence of pregabalin misuse among both BDZ abusers and non-abusers and patients with depressive symptoms supports both the inclusion of routine monitoring for pregabalin and intervention in MMT population.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>29857329</pmid><doi>10.1016/j.drugalcdep.2018.04.025</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-7091-7987</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0376-8716 |
| ispartof | Drug and alcohol dependence, 2018-08, Vol.189, p.8-11 |
| issn | 0376-8716 1879-0046 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2049556053 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); Access via ScienceDirect (Elsevier) |
| subjects | Abusers Benzodiazepines Benzodiazepines (BDZ) Cannabis Depression Drug abuse Drug addiction Drug use Health care facilities Hepatitis Hepatitis C HIV Human immunodeficiency virus Marijuana Medical diagnosis Medical treatment Mental depression Methadone Methadone maintenance treatment (MMT) Narcotics Opiates Opioids Oxycodone Patients Pregabalin Prescription drugs Rewards Risk analysis Risk factors Severity Substance abuse Symptoms Urine Urine tests |
| title | Pregabalin misuse in methadone maintenance treatment patients in Israel: Prevalence and risk factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A55%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pregabalin%20misuse%20in%20methadone%20maintenance%20treatment%20patients%20in%20Israel:%20Prevalence%20and%20risk%20factors&rft.jtitle=Drug%20and%20alcohol%20dependence&rft.au=Sason,%20Anat&rft.date=2018-08-01&rft.volume=189&rft.spage=8&rft.epage=11&rft.pages=8-11&rft.issn=0376-8716&rft.eissn=1879-0046&rft_id=info:doi/10.1016/j.drugalcdep.2018.04.025&rft_dat=%3Cproquest_cross%3E2100878650%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2100878650&rft_id=info:pmid/29857329&rft_els_id=S0376871618302916&rfr_iscdi=true |